The EPB41L4B antibody is a tool used to detect the EPB41L4B protein, encoded by the *EPB41L4B* gene in humans. This gene belongs to the FERM domain-containing 4.1 superfamily, which regulates cytoskeletal-membrane interactions, cell adhesion, and signaling. EPB41L4B (Erythrocyte Membrane Protein Band 4.1 Like 4B), also termed YMO1 or FRMD6L, is implicated in cell polarity, proliferation, and tumor suppression. Studies suggest its role in Hippo signaling, a pathway critical for organ size control and cancer prevention. Dysregulation of EPB41L4B has been linked to cancers, neurological disorders, and metabolic diseases. The antibody is commonly used in research applications like Western blotting, immunohistochemistry, and immunofluorescence to study protein expression, localization, and interaction partners. Commercially available antibodies are typically raised in rabbits or mice, with validation including knockout cell lines or recombinant protein controls. Researchers rely on its specificity to explore EPB41L4B's molecular functions, particularly its tumor-suppressive mechanisms and cross-talk with pathways like Wnt or mTOR. However, variability in antibody performance across experimental conditions requires rigorous validation for reproducibility. Ongoing studies aim to clarify its therapeutic potential in precision medicine.